Pharmalot Generic makers will appeal ruling that allows California to proceed with law banning pay-to-delay deals By Ed Silverman @Pharmalot
January 3, 2020
MARK RALSTON/AFP/Getty Images
A federal judge dealt the pharmaceutical industry a setback by declining to block a new California law that bans so-called pay-to-delay deals between drug makers, prompting an industry trade group to pursue an appeal with a higher court.
The move comes after the Association for Accessible Medicines filed a lawsuit two months ago to thwart the state law, which was the first in the nation to outlaw pay-to-delay deals. California officials explained the step was necessary in order to prevent drug companies from thwarting competition and maintaining higher prices for medicines.
Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!
GET STARTED Log In | Learn More What is it? STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included? Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day Online intelligence briefings Frequent opportunities to engage with veteran beat reporters and industry experts Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. GET STARTED
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology